Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa

Key facts

Sponsor

International Maternal Pediatric Adolescent AIDS Clinical Trials Group

Principal Investigator

Lisa Marie Cranmer, MD, MPH

Emory University

Intervention

VPM1002 Vaccine(biological)

Eligibility

8-14 years · All sexes

Timeline

2025 – 2025

Study locations (9)

• Soweto IMPAACT CRS, Johannesburg, Gauteng, South Africa
• Setshaba Research Centre CRS, Soshanguve, Gauteng, South Africa
• Isipingo CRS, Soshanguve, KwaZulu-Natal, South Africa
• Klerksdorp CRS, Klerksdorp, North West, South Africa
• Desmond Tutu TB Centre - Stellenbosch University (SU) CRS, Cape Town, Western Cape, South Africa
• Emavundleni CRS, Cape Town, Western Cape, South Africa
• Umlazi CRS, Durban, South Africa
• Wits RHI Shandukani Research CRS, Johannesburg, South Africa
• Family Clinical Research Unit (FAM-CRU) CRS, Tygerberg Hills, South Africa

Collaborators

National Institute of Allergy and Infectious Diseases (NIAID) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · National Institute of Mental Health (NIMH)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary genito-urinary tuberculosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT05917210
  Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
  Yale University
• RECRUITINGNCT07312266
  Questioning the Epidemiology of Asymptomatic TB
  Barcelona Institute for Global Health
• RECRUITINGNANCT05842161
  South Africa Smoking Cessation and Engagement in HIV/TB Care Care
  Massachusetts General Hospital
• RECRUITINGPHASE3NCT05575518
  A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis
  Stellah Mpagama
• ACTIVE NOT RECRUITINGPHASE4NCT05118490
  Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
  The Aurum Institute NPC
• RECRUITINGNANCT05342064
  Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service
  Baylor College of Medicine

See all trials for Primary genito-urinary tuberculosis →